INTRODUCTION
Statins are used in dyslipidemia as well as coronary heart disease either with or without significant hyperlipidemia. There are several studies [1] [2] [3] [4] favoring the long-term use of statins in ischemic heart disease and peripheral vascular disorders. Statins could also be beneficial in these conditions due to their pleiotropic effects 5 such as "improving endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response." 5 However, some of the recent studies have shown that statins may cause impairment of cognition, glucose tolerance, and Vitamin D metabolism. 6 Cholesterol is the precursor for vitamin D synthesis. Statins by reducing cholesterol synthesis may lead to a reduction in vitamin D level. However, recently it has been reported that statins can compete with vitamin D for metabolism and increase its level.
vitamin D level in patients who are on statins and those not on statins.
METHODS
• The study was a prospective cross-sectional study • It was initiated after obtaining approval from the Institutional Human Ethics Committee • Informed consent was obtained from participants prior to the study • Selection criteria:
• Statin group -all subjects who were on any one of statins for more than 1 year • Control group -apparently healthy individuals who were not suffering from any known medical disorders.
• From the subjects, the following information was collected:
• Age, gender, occupation, duration of statin therapy, name of statin taken, medical history including adverse effects such as myalgia and vitamin D supplementation.
• Subjects who were on vitamin D supplementation were excluded from the study in both statin and control groups • From the eligible subjects, 5 ml of blood was collected by direct venous puncture • Vitamin D (total) was estimated with the high sensitive chemiluminescence immunoassay method • Sufficient: 30-100 ng/ml • Insufficient: 20-29 ng/ml • Deficient: <20 ng/ml.
RESULTS
In this study, a total of 125 subjects participated. 60 subjects were in statin group and 65 in the control group. In statin group, 28 (47%) were males and 32 (53%) females. In control group, 35 (54%) were males and 30 (46%) females. The mean age of the subjects in statin group was 69.35±9.88 years (mean±standard deviation) and control group; it was 54.85±15.26 years. In statin group, 40 subjects were on atorvastatin, 19 on rosuvastatin, and 1 on simvastatin.
The mean vitamin D level in statin group was 15.82 ng/ml±11.51 and in the control group, 20.57 ng/ml±7.07. The gender and age wise summary of vitamin D level in both the groups is provided in Tables 1 and 2 .
In control group, vitamin D status was insufficient level (30-100 ng) in 9 subjects (13.85%), insufficient in 24 (36.92%), and deficient in 32 (49.23%) subjects. In statin group, vitamin D status was sufficient in 6 (10%) subjects, insufficient in 11 (18.33%) and deficient in 43 (71.67%) subjects ( Table 3 ).
The data of vitamin D level and vitamin D status is graphically represented in figure 1 and 2 respectively
Statistical comparison was made for vitamin D level using independent samples t-test as well as vitamin D status using Chi-square test which indicated a significant difference between the two groups (p=0.006 and 0.033, Table 4 ).
Age and gender difference did not have any influence on vitamin D level in both the groups. Within the statin group, there was no difference between atorvastatin and rosuvastatin. As there was a single patient in simvastatin group, it was not included for statistical comparison ( Table 5) .
Myalgia was reported by 30 out of 60 subjects (50%) in statin group and 5 out of 65 subjects (7.69%) in controls.
The difference was found to be highly significant (p=0.00). The present study has revealed that subjects on statin therapy had low vitamin D level compared to normal control subjects. The reason for such low level of vitamin D could be that statins reduce synthesis of cholesterol which is the precursor of vitamin D and make less cholesterol available for vitamin D synthesis. On the contrary, Schwartz 7 reported that statin increases vitamin D level as both undergo hepatic metabolism through the same pathway. Due to competitive inhibition of vitamin D metabolism by statins, its level is rather increased with concomitant statin therapy.
DISCUSSION
In our study, the statin group had at least 25% lower vitamin D level compared to control group. The mean vitamin D level in patients taking statins for more than 1 year was 15.82 ng/ml and in controls, 20.57 ng/ml. 71.67% of Vitamin D more than 30 ng/ml is considered to be sufficient. In our study only 13.85% of the control subjects had sufficient vitamin D level, and the remaining subjects (86.15%) had either insufficient or deficient vitamin D level. This observation is in accordance with the data reported in different studies, 9,10 which have observed that vitamin D is not sufficient in more than 70% of Indian population.
10% of subjects in statin group had sufficient vitamin D level, and the remaining 90% of subjects were in insufficient or deficient status.
Though there is no significant difference between statin and control group with regard to percentage of patients having normal vitamin D level, the percentage of patients having vitamin D deficiency was very high in statin group (71.67%) compared to control group (49.23%).
It can be postulated that vitamin D deficiency could have additionally contributed to stain induced myalgia and whether vitamin D supplementation can be recommended to all patients on statin therapy has to be explored. This is especially important when vitamin D deficiency is reported to be highly prevalent in normal subjects 8, 9 and whether universal vitamin D supplementation will prevent vitamin D deficiency related health issues is not known. [13] [14] [15] [16] Though this cross-sectional study observes that statin produces lower vitamin D level, long-term studies are required to investigate the changes in vitamin D level at multiple time points in response to statin therapy.
CONCLUSION
In this study carried out in 125 subjects, 10% of control subjects and 13.85% of statin group had normal vitamin D level. Statin group had significantly lower vitamin D level, compared to control. 71.67% of subjects in statin group had vitamin D deficiency while only 49.23% of control subject had vitamin D deficiency. It is concluded that statin therapy results in significant reduction in vitamin D level compared to normal control subjects.
